|
Atherosclerosis
|
0.400 |
Therapeutic
|
disease |
CTD_human |
A novel atheroprotective role of MF59-like adjuvant when co-administered with CETP vaccine in rabbit model of atherosclerosis.
|
28096968 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
A selective peroxisome proliferator-activated receptor δ agonist PYPEP suppresses atherosclerosis in association with improvement of the serum lipoprotein profiles in human apolipoprotein B100 and cholesteryl ester transfer protein double transgenic mice.
|
26683793 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation.
|
27454452 |
2016 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The hypothesis that CETP inhibition reduces atherosclerotic cardiovascular disease risk is still untested.
|
26848159 |
2016 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taq 1B polymorphism of cholesterol ester transfer protein (CETP) gene contributes to the development of atherosclerosis, whereas haplotypes of APOA5, APOC3, APOC4, and APOC5 genes are in the same cluster and are independently associated with high plasma triglyceride level, CAD and T2DM.
|
25470794 |
2015 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Osteoarthritis development is induced by increased dietary cholesterol and can be inhibited by atorvastatin in APOE*3Leiden.CETP mice--a translational model for atherosclerosis.
|
23625977 |
2014 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We review the genetics of CETP and coronary disease, preclinical data on CETP inhibition and atherosclerosis, and the effects of CETP inhibition on cholesterol efflux and reverse cholesterol transport.
|
24422575 |
2014 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Female APOE*3-Leiden.CETP mice, a model with human-like lipoprotein metabolism, were fed a cholesterol-containing Western-type diet for 5 weeks to induce atherosclerosis and subsequently treated for 4 weeks with exendin-4.
|
24490861 |
2014 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
These results show that the Fc-CETP6 vaccine efficiently elicited antibodies against CETP and reduced susceptibility to both atherosclerosis and steatohepatitis induced by the HFC diet.
|
25486007 |
2014 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Single nucleotide polymorphisms in cholesteryl ester transfer protein gene and recurrent coronary heart disease or mortality in patients with established atherosclerosis.
|
23891427 |
2013 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The role of cholesteryl ester transfer protein (CETP) in the development of atherosclerosis is under debate.
|
22854712 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
In the present study we analyzed the impact of different FXR agonists on cholesterol homeostasis, plasma lipoprotein profiles, and transhepatic cholesterol efflux in C57BL/6J mice and cynomolgus monkeys and atherosclerosis development in cholesteryl ester transfer protein transgenic (CETPtg) low-density lipoprotein receptor (LDLR) (-/-) mice.
|
22918042 |
2012 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study investigated whether the CETP gene I405V and Taq1B polymorphisms modified subclinical atherosclerosis in an asymptomatic Brazilian population sample.
|
23039379 |
2012 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
ATP-binding cassette transporter A1 (ABCA1), hepatic lipase (HL, coding genes named LIPC) and cholesteryl ester transfer protein (CETP) are important components of high-density lipoprotein (HDL) metabolism and reverse cholesterol transport (RCT) implicated in atherosclerosis and neurodegenerative diseases.
|
23181436 |
2012 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Decreasing CETP activity has consistently inhibited atherosclerosis in animal models.
|
21122682 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The inhibition of CETP can lead to substantial elevations in HDL-C. Based on a number of considerations, including the complex relationship between loss of function mutations in CETP and risk for CAD and the clinical experience with torcetrapib, it is difficult to predict if CETP inhibition will be associated with reductions in rates of atherosclerosis disease progression and risk for cardiovascular events.
|
21909703 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Here, we review the complex relationship between CETP and atherosclerosis based upon the experimental, clinical, and epidemiological studies.
|
21488146 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The RCT benefit in CETP-tg mice elicited by exercise training helps to elucidate the role of exercise in the prevention of atherosclerosis in humans.
|
21479674 |
2011 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We verified the effects of varying activities of plasma CETP on postprandial lipemia and precocious atherosclerosis in asymptomatic adult women.
|
21609439 |
2011 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The cholesteryl ester transfer protein (CETP) has a central role in the lipid metabolism and therefore may alter the susceptibility to atherosclerosis.
|
21899732 |
2011 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In clinical trials, CETP inhibitors increase HDL levels and reduce LDL levels, and therefore may be used as a potential treatment for atherosclerosis.
|
21787337 |
2011 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Taq1B polymorphism of cholesteryl ester transfer protein (CETP) is believed to associate with high-density lipoprotein-cholesterol (HDL-C) levels and may alter the susceptibility to atherosclerosis.
|
20799898 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
By shifting cholesterol in plasma from HDL to (V)LDL in exchange for VLDL-TG, CETP aggravates atherosclerosis in hyperlipidemic APOE*3-Leiden (E3L) mice.
|
19564641 |
2010 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
CETP restores HDL-C levels in SR-BI(KO) mice, but it does not change the susceptibility to atherosclerosis and other typical characteristics that are associated with SR-BI disruption.
|
20431066 |
2010 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
However, discussions regarding the role of CETP-mediated lipid transfer in the development of atherosclerosis and CETP inhibition as a potential strategy for prevention of atherosclerosis have been controversial.
|
20556633 |
2010 |